Providing the Food and Drug Administration (FDA) with a statutory pathway for approving safe, effective, and lower-cost versions of biotech drugs can help improve the lives of people with multiple sclerosis (MS) and other diseases. As Congress works toward re-authorizing the Prescription Drug User Fee Act (PDUFA), it makes sense to attach FDA-related legislation that would also advance generic versions of biotech drugs. Click here to take action on this issue. Many people living with MS depend on biologic drugs to sustain or improve their quality of life. But the cost of biologic drugs ($16,500 to $26,000 each year) can force many to stop their prescribed therapies because they cannot afford them. Currently, no generic alternatives are available for this fast-growing and expensive category of drugs.
The Access to Life-Saving Medicine Act — introduced by Congressman Waxman — would provide a statutory pathway for the FDA to review and approve safe, effective, and affordable generic biological therapies. The House Energy and Commerce Committee currently is discussing this issue. MS activists are taking action.
No comments:
Post a Comment